AUTHORS
Taylor R. Brooks, MD, Kwang Wooahn, PhD2, Tiening Chen, MS3, Jinalben Patel, MPH, BDS4, Peter Riedell5, Craig Sauter, MD6, Alex Francisco Herrera, MD7, Mazyar Shadman, MD, MPH8, Mehdi Hamadani, MD9, Cameron J. Turtle, MBBS, PhD10, Yifan Pang, MD11
AFFILIATIONS
1 Cleveland Clinic, Cleveland, Ohio, United States
2 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
3 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
4 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
5 University of Chicago, Chicago, Illinois, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 City of Hope National Medical Center, Duarte, California, United States
8 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
9 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
10 The University of Sydney, Sydney, New South Wales, Australia
11 Alaska Native Medical Center, Anchorage, Alaska, United States
ABSTRACT
Introduction: Enteropathy-associated T-cell lymphoma (EATL) and monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) are rare, aggressive intestinal T-cell lymphomas without a widely accepted standard of care. Hematopoietic cell transplantation (HCT) is used for remission consolidation or salvage, but supporting evidence comes from small series. We describe transplant practice and outcomes for both entities in the CIBMTR registry.
Methods: Adults (age ≥ 18 years) with EATL or MEITL undergoing first autologous HCT (auto) or allogeneic HCT (allo) between 2008 and June 2024 and reported to the CIBMTR were included (MEITL was captured as a distinct histology in CIBMTR forms from 2018 onward; cases transplanted earlier are recorded as EATL and could not be reclassified). Any donor type and conditioning intensity were included. Ex vivo graft manipulation was excluded. Data cut off was May 6, 2025. The primary endpoint was overall survival (OS); secondary endpoints were hematopoietic recovery, acute and chronic graft-versus-host disease (aGVHD and cGvHD) rate, non-relapse mortality (NRM), cumulative incidence of relapse (CIR), progression-free survival (PFS) and GVHD-free, relapse-free survival (GRFS). OS/PFS/GRFS were estimated by Kaplan-Meier and relapse, NRM and GVHD by cumulative incidence accounting for competing risks. Univariable Cox models were restricted to EATL auto due to sample size.
Results: 194 patients were included: EATL auto (n=122), EATL allo (n=26), MEITL auto (n=34) and MEITL allo (n=12). Median age was 60.6 years (22.0-77.6), 69.6% were male and 64.4% White. Median time from diagnosis to HCT was 6.9 months (2.3-179.6) and 72.7% were in complete remission (CR) at HCT; CR at transplant was more frequent among auto (75.4% EATL, 79.4% MEITL) than allo recipients (57.7% and 58.3%). Prior-line data were available for 89 (45.9%) patients, of whom 67.4% were transplanted after one prior line. Reduced intensity or non-myeloablative conditioning (RIC/NMA) was used in 68% of allo patients.
Median follow-up was 59.4 months. Among auto recipients, 2-year OS was 64.2% (95% confidence interval, 54.9-73.0%) in EATL and 55.7% (37.1-73.5) in MEITL, with 2-year PFS of 56.3% (46.9-65.4) and 39.7% (22.4-58.4), respectively. Among allo recipients, 2-year OS was 21.6% (8.0-39.7) in EATL and 31.3% (8.6-60.3) in MEITL, with 2-year PFS of 17.6% (5.4-34.9) and 25.0% (5.7-52.1), respectively. One-year CIR was highest in MEITL allo, 58.3% (28.1-85.5). One-year GRFS was 37.5% (16.2-61.8) for EATL allo and 9.1% (0-32.0) for MEITL allo.
Hematopoietic recovery was high across all four cohorts (28-day neutrophil recovery, 83.3-100%; 100-day platelet recovery, 81.8-97.1%). Among allo recipients, 6-month grade 2-4 aGVHD was 36.4% (MEITL) and 12.5% (EATL), grade 3-4 aGVHD 27.3% and 0%, and 1-year chronic GVHD 33.3% and 30.8%, respectively.
Among EATL auto recipients with available prior-line data (n=4), receipt of 2 prior lines of therapy was associated with inferior PFS (HR 3.81, 95% CI 1.20-12.10; p=0.02) but not OS. Age, sex, HCT-CI, Karnofsky score, time from diagnosis to HCT, disease status at HCT and year of transplant were not associated with outcome.
Conclusions: Here we report the largest transplant series reported for EATL and MEITL. Auto HCT recipients, most in CR and transplanted within a year of diagnosis, achieved 2-year OS exceeding 50% (64% EATL, 56% MEITL), supporting the feasibility and effectiveness of auto-HCT for chemosensitive patients. Allo recipients were less often in CR prior to transplant and had poor post-transplant outcomes. Across all groups, relapse rather than NRM dominated treatment failure, suggesting that improved outcomes following transplant among these patients is primarily influenced by more effective disease control before and after HCT. Our findings are hypothesis-generating, limited by small sample size, and confounding by indication. In addition, because MEITL was recorded as a distinct histology only from 2018, earlier cases could not be reclassified and are captured as EATL; the MEITL cohort therefore reflects contemporary practice, whereas the EATL cohort may contain some unrecognized MEITL. Our study provides a benchmark against which prospective trials of novel frontline and post-transplant therapies in EATL and MEITL can be powered and interpreted and suggests that deepening pre-transplant remissions may hold the greatest promise in improving long-term outcomes for these patients.
DISCLOSURES
Taylor R. Brooks, MD: No relevant conflicts of interest to declare.